A study evaluating Adalimumab versus Infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
Latest Information Update: 06 Nov 2017
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Infliximab
- Indications Crohn's disease
- Focus Therapeutic Use
- 06 Nov 2017 New trial record